AM Rx Review
Semaglutide GLP-1 weight-loss telehealth · Independently scored 5.4/10
Best for: compounded semaglutide at $151/month
AM Rx falls below our bar on medical oversight. Read the breakdown below before you give it money.
Covered by the monthly price
Medication
Not stated
Clinician visits
Not stated
Shipping
Not stated
Lab work
Not stated
Coaching
Not stated
No insurance needed · Vetted by our editors
AM Rx (getamrx.com) is a telehealth platform operated by FitRX, LLC, which also operates Zealthy and FitRx. Compounded semaglutide starts at $151/mo on a quarterly plan, and brand-name GLP-1s, Ozempic, Wegovy, Zepbound, and Mounjaro, come with insurance coordination as low as $25/mo. Consultations can be video or async. HSA/FSA accepted.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to AM Rx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
AM Rx at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Wegovy, Ozempic, Zepbound, Mounjaro
- Starting price
- $25/mo (As low as $25/mo with insurance coordination; a separate AM Rx membership is still required.)
- FDA status
- 3 FDA warning letters on record — see below
How AM Rx scores
Six columns, each one computed from something AM Rx has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
6.6/10$151/month is 20% below the register median of $189 for compounded semaglutide.
Effectiveness25%
9.0/10Dispenses semaglutide, including the FDA-approved product. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
2.5/10On the seller's own pages, no price appears until the medical intake is finished; a live video visit is required, which is slower but is the more careful intake.
Trust & Safety15%
1.0/103 FDA warning letters on record; does not name a dispensing pharmacy; withholds price until after the intake. Our verification confidence is medium.
Accessibility10%
5.0/10Publishes no list of states served, so coverage cannot be confirmed either way. Capped at the midpoint — this measures disclosure, not reach.
Support10%
5.0/10States too little about what the monthly cost covers to score the bundle. Held at the midpoint rather than assumed.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on AM Rx
Last checked August 2026- Re-read the price on file across 3 dose or plan tiers
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: medium.
What signing up with AM Rx involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1AM Rx does not show a price until you have worked through its medical questionnaire. Budget for the fact that you cannot compare it against anything until you have handed over health information.
- 2The intake requires a live video visit with a clinician, which is more than most of the register asks and slower to complete.
- 3AM Rx does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- Cheapest standing monthly prices on record: semaglutide $151. Membership fees, first-month rates and insured copays are excluded from those figures.
- No state list is published, so whether AM Rx serves your state cannot be confirmed from its site.
- 3 FDA warning letters on record. The letter itself is linked in the enforcement section below — read what it alleges rather than the fact that it exists.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
AM Rx support, as documented
- Phone
- (585) 699-1164
- support@getamrx.com
GLP-1 medications AM Rx offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
As low as $25/mo with insurance coordination; a separate AM Rx membership is still required.
Medication only ($151/mo when purchased quarterly); the recurring AM Rx membership is billed on top.
Standard $135/mo membership, $39 first month ($96 off promo); renews monthly. Medication is billed separately. drug omitted intentionally.
Check the price yourself before you pay
Every figure here was read off AM Rx's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $151 a month, within the normal band around this register's $189 median for the same drug and form
- A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake
Against it
- No price appears until the medical intake is complete, so the cost cannot be compared before health information is submitted
- No state list is on record here, so whether it serves your state cannot be confirmed from this page
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 3 FDA warning letters matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality
What AM Rx charges
AM Rx lists $151/month. That sits at the affordable end of what we track.
- Brand-name semaglutide — $25/month
- Compounded semaglutide — $151/month
- Required AM Rx membership (subscription, separate from medication) — $39 first month, then $135/month
Across the GLP-1 providers in our register the median standing price is about $169/month, so AM Rx is genuinely under the middle rather than merely advertising that it is.
Found dispenses semaglutide and tirzepatide from $149/month, which makes it the honest comparison to run before committing here.
What AM Rx dispenses
AM Rx prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the pair carrying the strongest published outcome data. You can take the approved brand pen or the cheaper compounded preparation. What separates them is review: the approved product went through it, the compounded one did not, and that is the whole of the trade.
What we could verify
AM Rx publishes little that can be checked from outside an intake. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You need to bill insurance. Like most of this market, this is cash-pay.
- A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.
It fits if
- the lowest standing monthly cost is what you are solving for
Our read
AM Rx competes on price, and at $151/month it competes well. The FDA letter on file is the thing to weigh against that, not a footnote to it. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.
The Bottom Line
AM Rx falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay AM Rx
Starting at $151/month. Check today's price, then book the free consultation.
Where AM Rx is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
AM Rx has an FDA warning letter on record, dated June 8, 2026
This letter concerns false & misleading claims/misbranded (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this AM Rx review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
See AM Rx's current pricing
Plans start at $151/month. The free consultation is where you learn whether you qualify, and what it costs today.